In patients presenting with synchronous or metachronous multiple lung cancer (MLC), it is important to distinguish between multiple primary lung cancer (MP) and intrapulmonary metastasis (IM). The present study was aimed at investigating the mutational profiles of synchronous/metachronous MLC and to compare the Of these, the paired tumors of four cases harbored multiple matching mutations, suggesting that the mutational diagnosis might be more suitable in these patients.
| INTRODUCTION
Recently, with the increasing availability of high-resolution computed tomography (CT) and high rates of CT screening for lung cancer, in addition to improvement of patient prognosis after primary lung cancer resection, the diagnostic frequency of synchronous/metachronous MLC has been increasing. 1 Determination of whether multiple lung cancer arises from the same clone (intrapulmonary metastasis)
or not (multiple primary) is of crucial importance in clinical cases, as it guides the management strategy and prediction of the prognosis.
In 1975, Martini and Melamed proposed criteria for distinguishing multiple primary lung tumors from pulmonary metastases. 2 Their criteria were, however, rather empirical, not definitive proof of clonality of multiple tumors, because they were mainly based on the histological characteristics of the tumors, tumor location, interval from resection, and presence/absence of carcinoma in situ, without consideration of the biological and/or molecular features of the tumors.
In lung cancer, the histological features of multiple lesions often show overlapping, especially in the case of adenocarcinomas. 3 Particularly, in such cases, it is still a challenge to distinguish between multiple primary tumors and multiple intrapulmonary metastases without information about molecular biological features.
Intratumor heterogeneity has been explained by the trunk and branch model. 4, 5 In this model, early somatic events which drive tumor growth are represented in every subclone and every tumor region as trunk mutations. With development of the disease, heterogeneous somatic events are represented in the primary lesions and/or the metastatic sites as branch mutations. These "branch" alterations may induce intratumor heterogeneity. According to this theory, multiple lesions harboring the same mutations are presumed to derive from the same clone. Recent advances in molecular biology have provided several markers that can be used for clonal analysis. Several studies have shown that mutations of some driver and suppressor genes, such as EGFR, KRAS and TP53, are useful as clonal markers in MLC. 6, 7 However, in most of these reports, only a limited number of gene mutations were analyzed, and the usefulness of mutational analysis of targeted genes to distinguish between MP and IM in patients with MLC remains controversial.
In the present study, we investigated the gene mutations of 20 targeted lung cancer-related genes in surgically resected specimens of synchronous/metachronous MLC using NGS technology. In addition, we compared our classification of paired tumors as MP or IM based on the mutational profile with the histopathological evaluation of the tumors. 
| MATERIALS AND METHODS

| Patient selection
| Statistical analysis
Overall survival (OS) was calculated from the date of primary surgery to the date of death from any cause. Survival curves were drawn using the Kaplan-Meier method, and differences between groups were compared by the log-rank test. Patients who were lost to follow up were censored on the date of last contact/follow up. Student's t test was applied to compare the scores between two independent groups. Fisher's exact test was applied to compare the ratios between two groups. All statistical analyses were carried out F I G U R E 3 Representative computed tomography (CT) images of multiple primary lung cancer (MP) and intrapulmonary metastasis (IM) cases. Arrows indicate each tumor. A, Case 4. Part-solid nodules were observed in the superior segment of the lower lung, and segmentectomy was carried out. This case was classified as IM by Martini and Melamed criteria, whereas it was diagnosed as MP by mutational evaluation because no matching mutations were observed. B, Case 32. A solid nodule was observed in the left upper lobe, and left upper lobectomy was carried out. Three years later, a small nodule was observed in the right upper lobe, and partial resection was carried out. This case was classified as MP by Martini and Melamed criteria, whereas it was diagnosed as IM by mutational evaluation because of multiple matching mutations (KRAS G12C and MET N375K)
using 
| Mutational profiling
Results of the mutational analysis are shown in Figure 1 . Information of allele frequency (AF) of each genetic mutation is listed in Table S3 . Median AF was 32%, ranging from 8% to 62%. Average coverage of sequencing across all samples was 1677, which is supposed to provide high sensitivity to detect mutations at low allele frequencies due to heterogeneous or low-purity specimens. Gene mutations were identified in 59 (72%) tumors, and 57 types of mutation were identified. EGFR mutation was the most frequently patients showed no mutations of the targeted genes in this study.
| Clinicopathological and mutational evaluation
We classified the paired tumors as MP or IM according to the Martini and Melamed criteria, histopathological and gene mutational evaluations. Martini and Melamed criteria are described in Table S4 .
According to the Martini and Melamed criteria, three patients were classified as IM cases, whereas the remaining were classified as MP cases. Based on the results of histopathological evaluation, seven patients (including three patients with metachronous MLC and four patients with synchronous MLC) were diagnosed as IM cases and 17
(including 12 patients with metachronous MLC and five patients with synchronous MLC) as MP cases (Table 2) , and the remaining (13 patients) were classified as equivocal cases (Table 2) 
| Survival analysis
Of the 37 patients, eight patients died by the time of the final data analysis in July 2017. Median survival time calculated for the entire study population was 103 months (range, 2-164 months). After exclusion of the histopathologically equivocal cases, there was no significant difference between the cases stratified by histopathological evaluation ( Figure 5A ). Similarly, no significant difference was observed between the cases stratified by mutational evaluation ( Figure 5B ).
| DISCUSSION
In patients with synchronous/metachronous MLC, distinguishing MP from IM is of crucial importance to clinicians, to enable them to select the appropriate therapeutic strategies and predict the prognosis with accuracy. The benefits of surgical resection have been demonstrated for MP, whereas systemic chemotherapy without surgery is recommended for most cases of IM. 9, 10 With the advances in high-throughput sequencing technologies, mutational analysis for specific driver and suppressor genes has been shown to be useful for distinguishing between multiple primary tumors and pulmonary metastases. [11] [12] [13] In recent years, in patients with MLC, several reports have been published of mutational analyses by NGS, which allows analysis for multiple gene mutations at once. 14, 15 In this study, we investigated the mutational profiles by NGS of 20 lung cancer-related genes in surgically resected paired tumors obtained from the same patients and compared the clinicopathological diagnoses with the diagnoses based on mutational evaluation. In histopathologically IM cases, we found a good concordance rate (86%) with the diagnosis based on the mutational evaluation. Contrastingly, in histopathologically MP cases, the concordance rate with the diagnosis based on the mutational evaluation was only 53%.
Several reports have shown high concordance rates (>90%) of gene mutations between the primary lesion and metastatic lesions. 16, 17 Conversely, high rates of discrepancy of driver mutations have been reported among synchronous multiple ground-grass lung nodules, which are considered to represent multiple independent lung cancer nodules. 18 In our cohort, most of the histopathologically IM cases were diagnosed as IM cases also by mutational evaluation. Among these, the paired tumors of five patients (cases 2, Regarding the survival analysis, no significant difference in the overall survival was observed between the cases stratified by histopathological or mutational evaluation. This could be explained by the highly selected cohort used in our study; namely, our cohort included cases with satellite lesions in the same lobe or oligometastases, which may be expected to be associated with a better prognosis with a surgical approach. 22, 23 If we had included not only operable patients, but also patients without indication for surgery,
we may have obtained a worse prognosis in the IM group.
Several limitations of the present study should be acknowledged.
First, the size of our study cohort was relatively small. The EGFR mutations were more frequently observed in Asians, and exon 19 deletion was the most frequently observed (48.2%), followed by L858R (42.7%). 24 Our data showed the relative low frequency of exon 19 deletion, but we have no reasonable explanation for this discrepancy. Further investigation regarding etiology of EGFR genotype in lung cancer is necessary. Second, we included operative cases only, which could have introduced a selection bias. Finally, the number of targeted genes in our NGS panel may be relatively small.
Recent studies on mutational analysis using NGS have included a larger number of targeted genes than we did. 14, 15 Begg et al indicated that at least 20 markers are required from a statistical perspective to distinguish between clonal and independent tumors with high accuracy. 25 In the present study, although we analyzed 20 lung cancerrelated genes, paired tumors from five patients (cases 10, 11, 14, 23, and 31) failed to show any mutations. This result may imply the lack of sufficient power of our panel. Further investigation and larger studies are necessary to resolve these problems.
Translocation of genes such as ALK/ROS1/RET is important to characterize lung cancer. 26 However, the DNA-based panel we used in this study could detect point mutations, small insertions and deletions only, because we emphasized low cost and convenience. More comprehensive analysis including gene fusions such as ALK/ROS1/ RET is expected to lead to more informative and interesting results for more accurate differentiation of multiple lung cancer.
In conclusion, mutational analysis of MLC for 20 targeted genes using NGS appears to be a useful complementary tool for distinguishing MP from IM in addition to histopathological evaluation. In histopathologically equivocal cases or cases with discordance between the histopathological and the mutational evaluation, consideration of the frequency and number of matching mutations may be helpful for the differentiation.
